Charter Trust Co. Invests $226,000 in Mylan (MYL)
Charter Trust Co. purchased a new position in Mylan (NASDAQ:MYL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,347 shares of the company’s stock, valued at approximately $226,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Meeder Asset Management Inc. lifted its position in shares of Mylan by 76.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after purchasing an additional 1,475 shares during the period. BT Investment Management Ltd acquired a new position in shares of Mylan in the 3rd quarter worth approximately $142,000. Doliver Capital Advisors LP acquired a new position in shares of Mylan in the 2nd quarter worth approximately $201,000. Parametrica Management Ltd acquired a new position in shares of Mylan in the 3rd quarter worth approximately $224,000. Finally, Highlander Capital Management LLC lifted its position in shares of Mylan by 16.2% during the 2nd quarter. Highlander Capital Management LLC now owns 7,175 shares of the company’s stock valued at $278,000 after acquiring an additional 1,000 shares during the period. Hedge funds and other institutional investors own 74.90% of the company’s stock.
In other news, CEO Heather M. Bresch sold 75,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.69% of the company’s stock.
Mylan (NASDAQ:MYL) last posted its earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter in the previous year, the company earned $1.38 EPS. The business’s revenue was down 2.3% compared to the same quarter last year. equities analysts forecast that Mylan will post 4.56 EPS for the current year.
A number of research analysts recently issued reports on MYL shares. Zacks Investment Research downgraded shares of Mylan from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. Cantor Fitzgerald set a $34.00 target price on shares of Mylan and gave the company a “hold” rating in a research report on Tuesday, October 31st. Guggenheim started coverage on shares of Mylan in a research report on Tuesday, December 12th. They set a “buy” rating and a $59.00 target price on the stock. Mizuho reiterated a “buy” rating and set a $37.00 target price on shares of Mylan in a research report on Tuesday, October 24th. Finally, Royal Bank of Canada boosted their target price on shares of Mylan from $32.00 to $37.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Mylan presently has a consensus rating of “Buy” and an average price target of $44.19.
ILLEGAL ACTIVITY NOTICE: “Charter Trust Co. Invests $226,000 in Mylan (MYL)” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/01/19/charter-trust-co-invests-226000-in-mylan-myl.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.